Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Thursday, 05 / 13 / 2021

Articles

Abstract

CASE REPORT

Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate

Xiliu Chen1,2Di Liu3,  Dongliang Yang1,2 and  Xin Zheng1,2,*

1  Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2  Joint International Laboratory of Infection and Immunity, Huazhong University of Science and Technology, Wuhan, Hubei, China
3  Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
*Correspondence to: Xin Zheng, Department of Infectious Diseases, Joint International Laboratory of Infection and Immunity, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. ORCID: https://orcid.org/0000-0001-6564-7807. Tel: +86-27-85726026, Fax: +86-27-85726398, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(2):269-273 DOI: 10.14218/JCTH.2020.00129
Received: November 25, 2020 Accepted: February 20, 2021 Published online: April 9, 2021

Abstract

The coronavirus disease 2019 (COVID-19) pandemic continues worldwide. We report here two cases of chronic hepatitis B patients with acute respiratory syndrome coronavirus 2 infection treated with tenofovir disoproxil fumarate who demonstrated a favorable outcome. This report adds some evidence that concurrent HBV infection may not worsen COVID-19 infection and tenofovir disoproxil fumarate treatment may have partial positive effect on COVID-19 rapid recovery.

Keywords

COVID-19, SARS-CoV-2, Chronic hepatitis B, Tenofovir disoproxil fumarate

Journal of Clinical and Translational Hepatology 2021 vol. 9, 269-273  [ Html  ] [ PDF Full-text ]

© 2021 Authors. This is an Open Access article distributed under the terms of the  Creative Commons Attribution-Noncommercial 4.0 License(CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 logo

You are here: Home